161 related articles for article (PubMed ID: 25224572)
21. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
22. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
23. Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022;82:602-10.
Steinberg RL; O'Donnell MA; Packiam VT
Eur Urol; 2023 Feb; 83(2):e54-e55. PubMed ID: 36404205
[No Abstract] [Full Text] [Related]
24. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
25. A plea for long-term surveillance in bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer.
Meijer RP; van Rhijn BW
Eur Urol; 2012 Mar; 61(3):508-9. PubMed ID: 22154727
[No Abstract] [Full Text] [Related]
26. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
[TBL] [Abstract][Full Text] [Related]
27. Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731.
Lamm DL
J Urol; 2008 Feb; 179(2):788. PubMed ID: 18082825
[No Abstract] [Full Text] [Related]
28. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
Brandau S
J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
[No Abstract] [Full Text] [Related]
29. Re: Pathological Stage Review is Indicated in Primary pT1 Bladder Cancer.
Wood DP
J Urol; 2011 Feb; 185(2):468. PubMed ID: 22088626
[No Abstract] [Full Text] [Related]
30. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
Hemdan T; Johansson R; Jahnson S; Hellström P; Tasdemir I; Malmström PU;
J Urol; 2014 May; 191(5):1244-9. PubMed ID: 24231843
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
[TBL] [Abstract][Full Text] [Related]
32. Re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85.
Lamm DL; Gandhi NM
Eur Urol; 2014 Jan; 65(1):e6. PubMed ID: 24148919
[No Abstract] [Full Text] [Related]
33. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
[TBL] [Abstract][Full Text] [Related]
34. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours.
Agundez M; Grau L; Palou J; Algaba F; Villavicencio H; Sanchez-Carbayo M
Eur Urol; 2011 Jul; 60(1):131-40. PubMed ID: 21514719
[TBL] [Abstract][Full Text] [Related]
36. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
37. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
38. Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guérin Therapy.
Kamat AM; Urbauer DL
Eur Urol; 2016 Feb; 69(2):203. PubMed ID: 26260001
[No Abstract] [Full Text] [Related]
39. Re: Amit R. Patel, Edmund S. Sabanegh, J. Stephen Jones, et al. Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol 2010;58:934-7.
Oliveira CA; Rodríguez O; Palou J; Palou-Redorta J
Eur Urol; 2011 Jul; 60(1):e7. PubMed ID: 21531073
[No Abstract] [Full Text] [Related]
40. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]